Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.

Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S
Cancer. 2011 117 (4): 809-18

PMID: 20922800 · DOI:10.1002/cncr.25473

MeSH Terms (17)

Administration, Oral Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Drug Administration Schedule Erlotinib Hydrochloride Female Humans Lung Neoplasms Male Middle Aged Patient Selection Prostaglandins Pyrroles Quinazolines Sulfonamides

Connections (2)

This publication is referenced by other Labnodes entities:

Links